Premium
Drug‐induced Sweet's syndrome secondary to hepatitis C antiviral therapy
Author(s) -
Gheorghe Liana,
Cotruta Bogdan,
Trifu Viorel,
Cotruta Cristina,
Becheanu Gabriel,
Gheorghe Cristian
Publication year - 2008
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2008.03724.x
Subject(s) - ribavirin , medicine , pegylated interferon , drug , alpha interferon , hepatitis c , hepatitis c virus , interferon , combination therapy , sweet's syndrome , antiviral therapy , hepatitis , sweet syndrome , virology , pharmacotherapy , antiviral drug , immunology , virus , chronic hepatitis , pharmacology , dermatology
Pegylated interferon‐alpha in combination with ribavirin currently represents the therapeutic standard for the hepatitis C virus infection. Interferon based therapy may be responsible for many cutaneous side effects. We report a case of drug‐induced Sweet's syndrome secondary to hepatitis C antiviral therapy. To our knowledge, this is the first reported case of Sweet's syndrome in association with pegylated interferon‐alpha therapy.